Literature DB >> 7627806

Type 1 interferon as an antiinflammatory agent: inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist.

Y Huang1, L M Blatt, M W Taylor.   

Abstract

The effect of two type 1 interferons (r-metIFN-con1 and IFN-alpha 2b) on the induction of specific cytokines and IL-1Ra in whole blood was examined. IFN-gamma was induced at low levels following treatment of diluted whole blood in some but not all subjects. IL-1Ra was induced by both r-metIFN-con1 and IFN-alpha 2b, but with 10- to 100-fold higher induction per ng IFN with r-metIFN-con1 than with IFN-alpha 2b. There was no detectable induction of TNF-alpha, IL-4, or IL-6 by either IFN. The effect of both IFN preparations was measured on LPS-induced inflammatory cytokines. Both IFN preparations inhibited the production of IL-1 beta when added to the diluted blood samples before LPS addition. However, neither IFN had any effect on IL-1 beta synthesis when added at the same time or after LPS induction. When added to total blood cells in the absence of LPS at low concentration (up to 100 pg/ml), IFN slightly stimulated IL-1 beta production, but at 1000 pg/ml or greater there was significant inhibition of IL-1 beta production. These results suggest that type I IFNs play a role in regulating the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7627806     DOI: 10.1089/jir.1995.15.317

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  21 in total

Review 1.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

Review 2.  Immune cell crosstalk in type 1 diabetes.

Authors:  Agnès Lehuen; Julien Diana; Paola Zaccone; Anne Cooke
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

Review 3.  The unfolding web of innate immune dysregulation in alcoholic liver injury.

Authors:  G Szabo; P Mandrekar; J Petrasek; D Catalano
Journal:  Alcohol Clin Exp Res       Date:  2011-02-01       Impact factor: 3.455

Review 4.  Alcoholic liver disease and the gut-liver axis.

Authors:  Gyongyi Szabo; Shashi Bala
Journal:  World J Gastroenterol       Date:  2010-03-21       Impact factor: 5.742

5.  Dose-dependent structural and immunological changes in the placenta and fetal brain in response to systemic inflammation during pregnancy.

Authors:  Anna Chudnovets; Jun Lei; Quan Na; Jie Dong; Harish Narasimhan; Sabra L Klein; Irina Burd
Journal:  Am J Reprod Immunol       Date:  2020-05-22       Impact factor: 3.886

6.  Conserved Gammaherpesvirus Protein Kinase Selectively Promotes Irrelevant B Cell Responses.

Authors:  Eric J Darrah; Christopher N Jondle; Kaitlin E Johnson; Gang Xin; Philip T Lange; Weiguo Cui; Horatiu Olteanu; Vera L Tarakanova
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

7.  Tyrosine kinase 2 controls IL-1ß production at the translational level.

Authors:  Marta Radwan; Rita Stiefvater; Tom Grunert; Omar Sharif; Ingrid Miller; Martina Marchetti-Deschmann; Günter Allmaier; Manfred Gemeiner; Sylvia Knapp; Pavel Kovarik; Mathias Müller; Birgit Strobl
Journal:  J Immunol       Date:  2010-08-16       Impact factor: 5.422

8.  Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients.

Authors:  A Kaser; D Novick; M Rubinstein; B Siegmund; B Enrich; R O Koch; W Vogel; S H Kim; C A Dinarello; H Tilg
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

9.  Toll-like receptors in the pathogenesis of alcoholic liver disease.

Authors:  Jan Petrasek; Pranoti Mandrekar; Gyongyi Szabo
Journal:  Gastroenterol Res Pract       Date:  2010-08-17       Impact factor: 2.260

10.  A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis.

Authors:  H Tilg; H Vogelsang; O Ludwiczek; H Lochs; A Kaser; J-F Colombel; H Ulmer; P Rutgeerts; S Krüger; A Cortot; G D'Haens; M Harrer; C Gasche; F Wrba; I Kuhn; W Reinisch
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.